CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-17 | QVT Financial LP Director by Deputization | Sale | −155,076 | $23.02 | $3.6M | 16,542,651 |
| 2025-12-17 | QVT Financial LP Director by Deputization | Sale | −189,538 | $23.17 | $4.4M | 16,353,113 |
| 2025-12-16 | Gold Daniel Allen Director | Sale | −275,000 | $22.93 | $6.3M | 17,772,727 |
| 2025-12-16 | Gold Daniel Allen Director | Sale | −642,282 | $23.08 | $14.8M | 17,130,445 |
| 2025-12-16 | MANCHESTER KEITH S Director | Sale | −275,000 | $22.93 | $6.3M | 17,772,727 |
| 2025-12-16 | MANCHESTER KEITH S Director | Sale | −642,282 | $23.08 | $14.8M | 17,130,445 |
| 2025-12-16 | QVT Financial LP Director by Deputization | Sale | −275,000 | $22.93 | $6.3M | 17,772,727 |
| 2025-12-16 | QVT Financial LP Director by Deputization | Sale | −642,282 | $23.08 | $14.8M | 17,130,445 |
| 2025-12-15 | Gline Matthew CEO | Option exercise | +234,096 | $4.06 | $950K | 17,521,177 |
| 2025-12-15 | Gline Matthew CEO | Sale | −230,357 | $21.68 | $5.0M | 17,290,820 |
| 2025-12-15 | Gline Matthew CEO | Other disposition | −3,739 | $21.68 | $81K | 17,287,081 |
| 2025-12-15 | Gline Matthew CEO | Option exercise | +1,363,711 | $12.68 | $17.3M | 18,650,792 |
| 2025-12-15 | Gline Matthew CEO | Sale | −566,116 | $21.68 | $12.3M | 18,084,676 |
| 2025-12-15 | Gline Matthew CEO | Other disposition | −797,595 | $21.68 | $17.3M | 17,287,081 |
| 2025-12-15 | Gline Matthew CEO | Option exercise | +2,272,852 | $12.68 | $28.8M | 19,559,933 |
| 2025-12-15 | Gline Matthew CEO | Sale | −943,527 | $21.68 | $20.5M | 18,616,406 |
| 2025-12-15 | Gline Matthew CEO | Other disposition | −1,329,325 | $21.68 | $28.8M | 17,287,081 |
| 2025-12-15 | Gline Matthew CEO | Option exercise · Stock Option (Right to Buy) | −234,096 | 0 | ||
| 2025-12-15 | Gline Matthew CEO | Option exercise · Stock Option (Right to Buy) | −1,363,711 | 0 | ||
| 2025-12-15 | Gline Matthew CEO | Option exercise · Stock Option (Right to Buy) | −2,272,852 | 0 |
Page 14 of 29 · 570 trades